Neonatal Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neonatal Seizures Market Outlook

Thelansis’s “Neonatal Seizures Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neonatal Seizures treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neonatal Seizures Overview

Neonatal Seizures represent the most distinctive frequent manifestations of neurological dysfunction in the neonatal period. Neonatal seizures are clinically described as abnormal, stereotyped and paroxysmal dysfunctions in the central nervous system (CNS) occurring within the first 28 days after birth in full-term infants or before 44 weeks of gestational age in preterm infants. It is a relatively common occurrence in neonates with a heterogeneous etiology, and most infants are acutely symptomatic. The etiologies are different in term and preterm infants. Hypoxic-ischemic encephalopathy (HIE), stroke, cerebral malformations and metabolic disorders are major causes of seizures in term infants. Some significant causes in preterm infants are intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL) and infections. Neonatal seizures are often the first clinical sign of underlying neurological dysfunction, with the most common causes being hypoxic-ischemic encephalopathy (HIE), perinatal stroke and intracranial haemorrhage. Due to the frequency of these conditions and the relative excitability of the newborn brain, the neonatal period, in particular the first week of life, is the most vulnerable period for the development of seizures.

• The incidence of neonatal seizures varies between 1 to 5 cases per 1000 live births, with significantly higher rates in premature infants ranging from 55 to 95 per 1000 live births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: